Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a structured recovery plan speed healing after emergency gallbladder surgery?

NCT ID NCT07695922

Disease control Sponsor: Hospital d'Igualada Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether a standardized care pathway called RICA helps people recover faster after emergency keyhole surgery for moderate gallbladder inflammation (Grade II acute cholecystitis). The pathway includes steps like ultrasound before surgery, limited fasting, blood sugar control, and goal-directed fluids during surgery. Researchers will compare patients who receive this structured care to a similar group who received usual care in the past, measuring how long they stay in the hospital after surgery and whether complications occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RICA perioperative care pathway (standardized recovery protocol)
What this could lead to
If successful, this could establish a standard recovery plan for emergency gallbladder surgery, helping patients leave the hospital sooner with fewer complications.
What could go wrong
This is a single-center, non-randomized study comparing a new protocol to past patients, so results may not apply broadly. The protocol is complex and may be hard to implement consistently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 to 85 years, inclusive. * Confirmed diagnosis of Grade II (moderate) acute cholecystitis based on the Tokyo Guidelines 2018 (TG18) criteria. * Patients scheduled for laparoscopic cholecystectomy within 72 hours of hospital admission and up to 10 days from symptom onset. * American Society of Anesthesiologists (ASA) physical status classification of I, II, or III. Exclusion Criteria: * Ongoing therapeutic anticoagulation or dual antiplatelet therapy that cannot be safely suspended or modified for surgery. * Concurrent advanced chronic liver disease (Child-Pugh class B or C), severe acute biliary pancreatitis, or associated complex biliary tract pathology. * Active SARS-CoV-2 (COVID-19) infection confirmed by polymerase chain reaction (PCR). * Refusal or inability to provide written informed consent for the prospective phase of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholecystectomy, laparoscopic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute cholecystitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cholecystectomy, laparoscopic Cholecystitis, acute Enhanced recovery after surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitari d'Igualada

    Igualada, Barcelona, 08700, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.